Fluoroquinolone's kill Quinsair

http://www.bioworld.com/content/orphan-firm-raptor-draws-doubt-praise-potential-418m-tripex-deal

Will the FDA allow Quinsair an inhaled fluoroquinolone that contains levofloxacin on to the US market next year? Lets hope not!

Pundits differed about Raptor Pharmaceutical Corp.'s buy of global rights to Quinsair for adult cystic fibrosis (CF) patients from Tripex Pharmaceuticals LLC for $68.4 million up front and as much as $350 million more in milestone payments.

Cowen and Co.'s Ritu Baral called clinical data “mixed” and found “little near-term value” in the acquisition, while analysts at JMP Securities “like this deal overall,” since it diversifies Raptor and “leverages [the firm's] existing sales footprint with only incremental adds needed.”

Used by CF patients with chronic pulmonary infections due to Pseudomonas aeruginosa, the twice-daily, inhaled fluoroquinolone contains levofloxacin, active against gram-negative and gram-positive bacteria. Quinsair was approved earlier this year in Europe as well as Canada, and Raptor intends to launch the compound in both territories in the first half of next year. The firm will consult the FDA about getting it approved in the U.S. …“ By Randy Osborne Staff Writer at http://www.bioworld.com .

Subject is play on “No Kill I” from Star Trek…

You could leave a comment if you were logged in.